We propose an end-to-end BigBiGAN-based DL approach to predicting the efficacy of EGFR-TKI therapy in patients presenting with stage IV EGFR variant–positive NSCLC without requiring manual tumor volume delineation or feature engineering procedures of traditional radiomics. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.